Company & Sponsor Intelligence
Neurocentria, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed2
Countries1
Therapeutic footprint
adhdalzheimers
Indexed studies
NCT05683249Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE2, PHASE3
adhd · United StatesPHASE2, PHASE3
NCT03531684Efficacy and Safety of MMFS in Early AD
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT06673368A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
adhd · United StatesPHASE2
adhd · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →